Q2 EPS Estimate for Sarepta Therapeutics Lifted by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Equities researchers at Zacks Research lifted their Q2 2025 earnings per share estimates for shares of Sarepta Therapeutics in a research report issued on Monday, October 21st. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings per share of $2.09 for the quarter, up from their previous estimate of $2.08. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $1.45 per share. Zacks Research also issued estimates for Sarepta Therapeutics' Q3 2025 earnings at $2.10 EPS, Q4 2025 earnings at $2.18 EPS, FY2025 earnings at $8.17 EPS and Q1 2026 earnings at $2.80 EPS.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The firm's revenue was up 38.9% on a year-over-year basis.

SRPT has been the subject of a number of other reports. Piper Sandler decreased their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an "overweight" rating for the company in a research note on Thursday, August 8th. Raymond James reiterated an "outperform" rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Needham & Company LLC restated a "buy" rating and issued a $205.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 14th. Cantor Fitzgerald restated a "neutral" rating and issued a $152.00 price target on shares of Sarepta Therapeutics in a research note on Friday, September 20th. Finally, Evercore ISI upgraded Sarepta Therapeutics from an "in-line" rating to an "outperform" rating and reduced their price objective for the stock from $185.00 to $179.00 in a research report on Thursday, August 8th. Two analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $182.95.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded up $1.46 during trading on Wednesday, reaching $129.88. 737,050 shares of the company's stock traded hands, compared to its average volume of 1,247,691. The stock has a market capitalization of $12.28 billion, a P/E ratio of 1,180.73 and a beta of 0.82. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $173.25. The company has a 50 day moving average of $128.87 and a 200-day moving average of $132.42. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19.

Institutional Trading of Sarepta Therapeutics

Large investors have recently added to or reduced their stakes in the company. Nordea Investment Management AB increased its holdings in shares of Sarepta Therapeutics by 120.6% in the 1st quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company's stock valued at $8,004,000 after purchasing an additional 33,711 shares during the period. Fifth Third Wealth Advisors LLC purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $607,000. Teachers Retirement System of The State of Kentucky purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $4,771,000. Securian Asset Management Inc. acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at $1,187,000. Finally, Natixis Advisors LLC purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $1,918,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Ian Michael Estepan sold 5,985 shares of the firm's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company's stock, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company's stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Andrew Chambers bought 37,038 shares of the firm's stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares of the company's stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.